Brief: Orchard Therapeutics QTRLY Loss Per Share $0.56
08/08/2019 12:19
Aug 8 (Reuters) - Orchard Therapeutics PLC ORTX.O :
* ORCHARD THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL
RESULTS AND BUILDS MOMENTUM AHEAD OF REGULATORY FILINGS
* ENDED Q2 OF 2019 WITH APPROXIMATELY $423M IN TOTAL CASH
AND
INVESTMENTS
* RECENT EQUITY FINANCING OF $130M EXTENDS CASH RUNWAY INTO
SECOND
HALF OF 202
* QTRLY LOSS PER SHARE $0.56
* Q2 EARNINGS PER SHARE VIEW $-0.36 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX3s6Tps
Further company coverage: ORTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln